JCJing Chen

Jing Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Li

    Nanjing University of Chinese Medicine, Nanjing, China

    3 shared publications
  • Lilin Ge

    Nanjing University of Chinese Medicine

    3 shared publications
  • Cheng Cheng

    Nanjing University of Chinese Medicine, Nanjing, China

    2 shared publications
  • Mengyang Huang

    Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

    2 shared publications
  • Mengyao Lv

    Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

    2 shared publications
  • Yao Lin

    Affiliated People’s Hospital, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian-Hong Kong-Macau-Taiwan Collaborative Laboratory for the Inheritance and Innovation of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, The Academy of Rehabilitation Industry, Fujian University of Traditional Chinese Medicine, China

    2 shared publications

Latest Publications

  • Open Access

    Lung adenocarcinoma cell-derived lactate activates CAFs to promote macrophage M2 polarization via exosomal miR-214-5p

    by Leilei Tao, Fengbiao Guo, Xiaobei Liu, Xiao Zhao, Ya Xue, Weigang Bian, Jing Chen, Shaoyi Zhang, Bin Li

    Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment that can drive cancer progression and immune evasion. Here, we identify a novel pathway in which lactate produced by lung adenocarcinoma (LUAD) cells activates normal fibroblasts into CAFs, inducing high expression of microRNA miR-214-5p. The CAFs secrete miR-214-5p via exosomes, which in turn polarizes tumor-associated macrophages (TAMs) toward the immunosuppressive M2 phenotype. Mechanistically, exosomal miR-214-5p targets the transcriptional repressor BHLHE41 in macrophages, relieving its inhibition on M2-polarization genes. We further demonstrate that lactate accumulation epigenetically upregulates miR-214-5p in CAFs by increasing histone H3 lysine 9 lactylation (H3K9la) at the DNM3OS/miR-214 gene locus, independently of the lactate receptor GPR81. Lactate also enhances the loading of miR-214-5p into exosomes by inducing lactylation of the RNA-binding protein YBX1, which binds miR-214-5p and facilitates its exosomal export. In a mouse co-implantation model of LUAD, pharmacological blockade of tumor lactate production (LDH inhibition) reduced CAF activation, TAM M2 polarization, miR-214-5p levels, and tumor growth. Our findings uncover a lactate-driven CAF-TAM signaling axis via exosomal miR-214-5p, highlighting potential therapeutic targets to counteract tumor immune evasion in lung adenocarcinoma.

  • Open Access

    YBX1 Confers immunosuppressive bone metastatic traits in non-small cell lung cancer

    by Kai Zhang, Bin Li, Qingshui Wang, Xiuli Zhang, Cheng Cheng, Mengyao Lv, Mengyang Huang, Zihui Liang, Zijie Xie, Yao Lin, et al.

    The spread of lung cancer to bone is a devastating complication often linked to resistance against immunotherapy, but the reasons for this connection are poorly understood. Here we show that the transcription factor YBX1 acts as a central regulator driving both bone metastasis and the formation of an immunosuppressive environment in non-small cell lung cancer (NSCLC). YBX1 achieves this by activating distinct signaling pathways (IL6 and CCL5, respectively). Mechanistically, YBX1 protein levels are controlled by glycosylation that marks it for autophagic degradation inside cells. Notably, reduced YBX1 glycosylation was observed in highly bone-metastatic NSCLC cells. Importantly, we identified a drug candidate, Icaritin, which boosts this sugar-modification, leading to YBX1 degradation. This dual action inhibits bone metastasis and re-sensitizes tumors to immune attack. Our work reveals YBX1 as a promising single target for combating bone spread and overcoming immunotherapy resistance.


  • Open Access

    Polarization of Tumor Cells and Tumor‐Associated Macrophages: Molecular Mechanisms and Therapeutic Targets

    by Guohao Wei, Bin Li, Mengyang Huang, Mengyao Lv, Zihui Liang, Chuandong Zhu, Lilin Ge, Jing Chen

    Tumor‐associated macrophages (TAMs) are prominent constituents of solid tumors, and their prevalence is often associated with poor clinical outcomes. These highly adaptable immune cells undergo dynamic functional changes within the immunosuppressive tumor microenvironment (TME), engaging in reciprocal interactions with malignant cells. This bidirectional communication facilitates concurrent phenotypic transformation: tumor cells shift toward invasive mesenchymal states, whereas TAMs develop immunosuppressive, pro‐tumorigenic traits. Increasing evidence highlights metabolic reprogramming, characterized by dysregulation of lipid metabolism, amino acid utilization, and glycolytic activity, as the fundamental molecular basis orchestrating this pathological symbiosis. However, a comprehensive understanding of how metabolic reprogramming specifically coordinates the mutual polarization of tumor cells and TAMs is lacking. This review thoroughly examines the molecular mechanisms governing this co‐polarization process, detailing critical transcriptional regulators, essential signaling pathways, and the maintenance of adaptive phenotypes within the TME. Furthermore, this review critically assesses promising therapeutic strategies aimed at disrupting this alliance, including the use of metabolically targeted agents, engineered chimeric antigen receptor macrophages, and TAM‐selective nanoparticle delivery systems. These insights provide a crucial foundation for the development of next‐generation cancer immunotherapies focused on reprogramming pathological polarization dynamics to overcome treatment resistance and improve clinical outcomes.


  • Bifunctional S-doping-mediated interfacial gradient electric field for in-situ amplified photoelectrochemical immunoassay

    by Bin Li, Jia Lin, Cheng Cheng, Haowen Zhang, Yuanyuan Guo, Yingru Zhi, Fan Cai, Yitong Zhang, Zhe Di, Houxi Xu, et al.